SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-20-021988
Filing Date
2020-02-14
Accepted
2020-02-14 17:00:59
Documents
5
Period of Report
2020-03-19
Effectiveness Date
2020-02-14

Document Format Files

Seq Description Document Type Size
1 DEF 14A tv537630-def14a.htm DEF 14A 546794
2 GRAPHIC lg_outlook-therapeutics.jpg GRAPHIC 405718
3 GRAPHIC tv537488_proxycard2.jpg GRAPHIC 652689
4 GRAPHIC tv537488_proxycard1.jpg GRAPHIC 496512
5 GRAPHIC tv537488_proxycard3.jpg GRAPHIC 812345
  Complete submission text file 0001104659-20-021988.txt   3808574
Mailing Address 7 CLARKE DRIVE CRANBURY NJ 08512
Business Address 7 CLARKE DRIVE CRANBURY NJ 08512 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37759 | Film No.: 20621575
SIC: 2836 Biological Products, (No Diagnostic Substances)